29 results found.

Gastric Cancer Clinical Trial using GDC-0068; Placebo; mFOLFOX6

Genentech - Recruiting 18 years or older.
- A Randomized, Phase II, Placebo Controlled Study of GDC-0068, an Inhibitor to Akt, in Combination With Fluoropyrimidine Plus Oxaliplatin in Patients With Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma.
GDC-0068; Placebo; mFOLFOX6

Metastatic Advanced Gastric Cancer Clinical Trial using Docetaxel 60 mg/m2, epirubicin 60 mg/m2, q3wks

Yonsei University - Recruiting 20 years or older.
- .
Docetaxel 60 mg/m2, epirubicin 60 mg/m2, q3wks

Gastric Cancer Clinical Trial using Olaparib; Paclitaxel; Placebo

AstraZeneca - Recruiting 18 years or older.
- A Randomized, Double-blinded, Placebo Controlled, Multicentre Phase III Study to Assess the Efficacy and Safety of Olaparib (AZD2281) in Combination With Paclitaxel, Compared to Placebo in Combination With Paclitaxel, in Asian Patients With Advanced Gastric Cancer (Including the Gastro-oesophageal Junction) Who Have Progressed Following First Line Therapy.
Olaparib; Paclitaxel; Placebo

Esophageal Cancer, or Gastric Cancer Clinical Trial using Afatinib (BIBW 2992)

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- A Phase II Study of Afatinib (BIBW 2992) in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer.
Afatinib (BIBW 2992)

Gastric Cancer Clinical Trial using trastuzumab emtansine; taxane

Hoffmann-La Roche - Recruiting 18 years or older.
- A Randomized, Multicenter, Adaptive Phase II/III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine (T-DM1) Versus Taxane (Docetaxel Or Paclitaxel) In Patients With Previously Treated Locally Advanced Or Metastatic Her2-Positive Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction.
trastuzumab emtansine; taxane

Stomach Neoplasms; Esophageal Neoplasms; Metastatic Gastric Cance Clinical Trial using AUY922; BYL719

Novartis - Recruiting 18 years or older.
- A Phase IB, Multicenter, Open-label Dose Escalation Study of the PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer Carrying a Molecular Alteration of PIK3CA or an Amplification of HER2.
AUY922; BYL719

Advanced HER2-positive Breast Cancer or Gastric Cancer Clinical Trial using LJM716; Trastuzumab

Novartis - Recruiting 18 years or older.
- A Multicenter, Open-label, Dose Escalation, Phase I Study of LJM716 Administered Intravenously in Combination With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast Cancer or Gastric Cancer.
LJM716; Trastuzumab

Advanced Gastric Cancer Clinical Trial using taxel plus raltitrexed; taxol

Fudan University - Recruiting 18 years to 75 years.
- Paclitaxel Plus Raltitrexed Plug Compare With Taxol Second-line Treatment for Advanced Gastric Cancer Stage II Randomized Controlled Clinical Studies.
taxel plus raltitrexed; taxol

Gastric Cancer Clinical Trial using Rilotumumab; Placebo

Amgen - Recruiting 18 years or older.
- A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG102) With Epirubicin, Cisplatin, and Capecitabine (ECX) as First-line Therapy in Advanced MET-Positive Gastric or Gastroesophageal Junction Adenocarcinoma.
Rilotumumab; Placebo

Locally Advanced (Unresectable) or Metastatic Adenocarcinoma of t Clinical Trial using Ipilimumab; Best Supportive care (BSC)

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Randomized, Open-label, Two-arm Phase II Trial Comparing the Efficacy of Sequential Ipilimumab Versus Best Supportive Care Following First-line Chemotherapy in Subjects With Unresectable Locally Advanced/Metastatic Gastric or Gastro-esophageal Junction Cancer.
Ipilimumab; Best Supportive care (BSC)

Gastric Cancer Clinical Trial

Hospital Miguel Servet - Recruiting 18 years or older.
- Circulating Exosomes As Potential Prognostic And Predictive Biomarkers In Advanced Gastric Cancer Patients: A Prospective Observational Study ('EXO-PPP Study').

Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesop Clinical Trial using oxaliplatin; leucovorin calcium; fluorouracil; therapeutic conventional surgery; radiation therapy; carboplatin; paclitaxel

Case Comprehensive Cancer Center - Recruiting 18 years or older.
- A Phase II Trial of Modified FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Response Based Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Adenocarcinoma of the Esophagus, Gastro-esophageal Junction, and Gastric Cardia.
oxaliplatin; leucovorin calcium; fluorouracil; therapeutic conventional surgery; radiation therapy; carboplatin; paclitaxel

Gastric Cancer Clinical Trial using RAD001

Chinese University of Hong Kong - Recruiting 18 years or older.
- Phase I/II Study of Paclitaxel / Carboplatin / RAD001 as First Line Therapy for Advanced Adenocarcinoma of the Stomach.
RAD001

Advanced Gastric Cancer, or Esophagogastric Junction Cancer Clinical Trial using Paclitaxel; RAD001

Krankenhaus Nordwest - Recruiting 18 years or older.
- A Randomized, Double-blind, Multi-center Phase III Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma Who Have Progressed After Therapy With a Fluoropyrimidine-containing Regimen.
Paclitaxel; RAD001

Gastric Cancer Clinical Trial using Cabazitaxel

Krankenhaus Nordwest - Recruiting 18 years or older.
- Multicentre, Phase II Study With Cabazitaxel in Previously Treated Patients With Advanced or Metastatic Adenocarcinoma of the Oesophagogastric Junction and Stomach.
Cabazitaxel

Advanced Gastric Cancer Clinical Trial using Docetaxel, Capecitabine, Cisplatin, Bevacizumab

Asan Medical Center - Recruiting 18 years to 70 years.
- A Phase II Study of Neoadjuvant Chemotherapy With Docetaxel, Capecitabine, Cisplatin, and Bevacizumab in Patients With Unresectable Advanced Gastric Cancer.
Docetaxel, Capecitabine, Cisplatin, Bevacizumab

Advanced Gastric Cancer Clinical Trial using Cisplatin, TS-1 and oxaliplatin

National University Hospital, Singapore - Recruiting 21 years or older.
- .
Cisplatin, TS-1 and oxaliplatin

Metastatic or Recurrent Gastric Adenocarcinoma, or Her-2 Positive Clinical Trial using Herceptin+XELOX

Asan Medical Center - Recruiting 20 years or older.
- A Phase II Study of Trastuzumab in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer.
Herceptin+XELOX

Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cance Clinical Trial using FOLFOX regimen; docetaxel; fluorouracil; irinotecan hydrochloride; leucovorin calcium; oxaliplatin

Southwest Oncology Group - Recruiting 18 years or older.
- A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1(Excision Repair Cross-Complementing 1) for Advanced/Metastatic Esophageal, Gastric or Gastroesophageal Junction (GEJ) Cancer.
FOLFOX regimen; docetaxel; fluorouracil; irinotecan hydrochloride; leucovorin calcium; oxaliplatin

Gastric Cancer Clinical Trial using LY2875358

Eli Lilly and Company - Recruiting 20 years or older.
- A Non-Randomized, Open-Label, Single-Arm, Phase 2 Study of LY2875358 in Patients With MET Diagnostic Positive, Advanced Gastric Cancer.
LY2875358

Breast Cancer, Gastric Cancer Clinical Trial using trastuzumab emtansine; capecitabine

Hoffmann-La Roche - Recruiting 18 years or older.
- PHASE I FOLLOWED BY PHASE II STUDY OF THE COMBINATION OF TRASTUZUMAB EMTANSINE (T-DM1) AND CAPECITABINE IN HER2-POSITIVE METASTATIC BREAST CANCER AND HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC GASTRIC CANCER PATIENTS.
trastuzumab emtansine; capecitabine

Gastric Cancer Clinical Trial using albumin-bounded paclitaxel; S-1

Chinese Academy of Medical Sciences - Recruiting 18 years or older.
- Pase 2 Study of Albumin-bounded Paclitaxel Plus S-1 as First-line Chemotherapy for Locally Advanced or Metastatic Gastric or Gastro-esophageal Adenocarcinoma.
albumin-bounded paclitaxel; S-1

Solid Tumors Clinical Trial using MSB0010718C

Merck KGaA - Recruiting 20 years or older.
- A Phase I Trial to Investigate the Tolerability, Safety, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Japanese Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion Part in Asian Subjects With Gastric Cancer.
MSB0010718C

Gastric Cancer Clinical Trial using surgery

Zhejiang Cancer Hospital - Recruiting 18 years to 70 years.
- Phase 2 Study of D2 and D2+ Radical Surgery for the Treatment of Advanced Distal Gastric Cancer.
surgery

Esophageal Cancer, or Gastric Cancer Clinical Trial using Oxaliplatin; Folinic Acid; 5-Fluorouracil; Ziv-aflibercept; Ziv-aflibercept Placebo

Dana-Farber Cancer Institute - Recruiting 18 years or older.
- Randomized, Double-Blind, Placebo Controlled Phase II Study of FOLFOX +/- Ziv-Aflibercept in Patients With Advanced Esophageal and Gastric Cancer.
Oxaliplatin; Folinic Acid; 5-Fluorouracil; Ziv-aflibercept; Ziv-aflibercept Placebo

Gastric Carcinoma Stage IV Clinical Trial using XELOX; FOLFOX

Dong-A University Hospital - Recruiting 20 years or older.
- A Phase III Trial to Evaluate the Efficacy and Safety of the Combination Therapy of Capecitabine and Oxaliplatin (XELOX) in Comparison to the Combination Therapy of Fluorouracil/Folinic Acid and Oxaliplatin (FOLFOX) in Patients With AGC.
XELOX; FOLFOX

Gastric Adenocarcinoma Clinical Trial using Oxaliplatin+S-1; Adjuvant Oxaliplatin/S-1(SOX)

Chinese PLA General Hospital - Recruiting 20 years to 75 years.
- Phase III, Randomized, Multicenter, Controlled Evaluation of S-1 and Oxaliplatin as Neoadjuvant Chemotherapy for Advanced Gastric Cancer Patients.
Oxaliplatin+S-1; Adjuvant Oxaliplatin/S-1(SOX)

Advanced Gastric Cancer Clinical Trial using endostar, cisplatin, capecitabine; capecitabine; cisplatin

Peking University - Recruiting 18 years to 75 years.
- A Phase II Study of Endostar (Recombinant Human Endostatin r) With Cisplatin and Capecitabine (Xeloda) as 1st Line Treatment in the Advanced Gastric Cancer.
endostar, cisplatin, capecitabine; capecitabine; cisplatin

Stomach Neoplasms Clinical Trial using S-1,Docetaxel

National Cancer Center, Korea - Recruiting 18 years to 70 years.
- Phase II Study of Perioperative S-1 Plus Docetaxel in Patients With Localized Advanced Gastric Cancer.
S-1,Docetaxel